BioSpace’s List of February 2019 Life Science IPOs

글 내용 전체보기

Top 5 Ways to Build a Great Rapport With Your Interviewer

글 내용 전체보기

Arcturus Surges Ahead in the mRNA Market, Regaining 100% Rights to OTC Deficiency Therapy

글 내용 전체보기

Korea Can’t Fill R&D Openings, While PhRMA Raises Concerns About the Country

글 내용 전체보기

Japan’s Love for Genentech’s Xofluza Flu Treatment May Be Waning

글 내용 전체보기

Artificial Intelligence Gaining Ground in Drug Development

글 내용 전체보기

NAD Boosters: Promising in Mice for Anti-Aging and Alzheimer’s, but Not Yet Ready for Prime-time

글 내용 전체보기

Exclusive: Take Heart! Life Science Industry Optimistic About Treating Heart Diseases

글 내용 전체보기

IFM Therapeutics Launches IFM Due, Its Second Subsidiary Aimed at Parkinson’s and NASH

글 내용 전체보기

AbbVie Partners With Teneobio, Secures Spot in BCMA Race to Treat Multiple Myeloma

글 내용 전체보기

Sanofi and Regeneron Cut Price of Cholesterol Med Praluent by About 60 Percent

글 내용 전체보기

Collaboration Of Waters And Pfizer Improves mAb And ADC Separations; Leads To New Column Chemistry

글 내용 전체보기

Merck’s Keytruda looks to zoom past Opdivo with fast head and neck cancer review

글 내용 전체보기

AbbVie loses bid to hoard documents in Humira patent fight with Boehringer

글 내용 전체보기

Dr. Reddy’s Bachupally plant experiences a version of FDA deja vu

글 내용 전체보기

대전협 “길병원 전공의 사망, 섣부른 추측 자제 부탁”

글 내용 전체보기

PCSK9 price-cut matchup is on, as Regeneron and Sanofi slash Praluent list tag 60%

글 내용 전체보기

KDDF 공개할 신약물질 30선 중 4개 미리 살펴보니

글 내용 전체보기

Will mutant strains hurt prospects for Roche’s flu-fighting newcomer Xofluza?

글 내용 전체보기

‘B형혈우병 유전자치료제’ 유니큐어, 스파크-화이자 추격

글 내용 전체보기

IFM Therapeutics launches cGAS/STING-focused subsidiary for inflammatory and autoimmune disease

글 내용 전체보기